Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 12, 2002, Pages 669-677

  Gabri, Mariano R ^a   Ripoll, Giselle V ^a   Alonso, Daniel F ^a   Gómez, Daniel E ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Breast cancer; GM3; Immunotherapy; Melanoma; Sialic acid

Indexed keywords

CANCER VACCINE; GANGLIOSIDE GM3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PEROXIDASE; SIALIC ACID;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CARCINOMA CELL; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; IMMUNIZATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; CELL DIVISION; CELL MEMBRANE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; G(M3) GANGLIOSIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; N-ACETYLNEURAMINIC ACID; NEISSERIA MENINGITIDIS;

EID: 0036456490     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0385-7     Document Type: Article

References (39)

1. Alonso DF, Farías EF, Urtreger A, Ladeda V, Vidal MC, Bal de Kier Joffé E (1996) Characterization of F3II, a mammary sarcomatoid carcinoma cell line originated from a mouse adenocarcinoma. J Surg Oncol 62:288-297
2. Alonso DF, Tejera AM, Farías EF, Bal de Kier Joffé E, Gomez DE (1998) Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res 18:4499-4504
3. Alonso DF, Gabri MR, Guthmann MD, Fainboim L, Gomez DE (1999) A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 15:59-66
4. Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE (2002) Cancer vaccines: An update with special focus on ganglioside antigens. Oncol Rep 9:267-276
5. Carr A, Mazorra Z, Alonso DF, Mesa C, Valiente O, Gomez DE, Perez R, Fernandez LE (2001) A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent, and non-transient antitumor activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res 11:219-227
6. Chapman PB, Lonberg M, Houghton AN (1990) Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res 50:1503-1509
7. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res 6:874-879
8. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649
9. Deng W, Li R, Ladisch S (2000) Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 92:912-917
10. Deng W, Li R, Guerrera M, Liu Y, Ladisch (2002) Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 12:145-152
11. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV, Fernandez LE (1999) Enhancement of the immune response to poorly immunogenic gangliosides after incorporation onto very small size proteoliposomes (VSSP). Vaccine 18:190-197
12. Harding CV, Roof RW, Allen PM, Unanue ER (1991) Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 88:2740-2744
13. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, Livingston PO (1994) GD3 vaccine for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54:197-203
14. Hersey P, Jamal O, Henderson C, Zardawi I, D́Alessandro G (1998) Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin naevi, primary and metastatic melanoma. Int J Cancer 41:336-343
15. Hirabayashi Y, Hamaoka A, Matsumoto M, Matsubara T, Tagawa M, Wakabayashi S, Taniguchi M (1985) Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma. J Biol Chem 260:13328-13333
16. Ishioka GY, Lamont D, Bulbow N, Gaeta FC, Sette A, Grey HM (1992) MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 148:2446-2451
17. Iwabuchi K, Yamamura S, Prinetti A, Handa K, Hakomori S (1998a) GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells. J Biol Chem 273:9130-9138
18. Iwabuchi K, Handa K, Hakomori S (1998b) Separation of "Glycosphingolipid Signaling Domain" from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. J Biol Chem 273:33766-33773
19. Livingston PO, Ritter G, Oettgen HF, Old J (1989) Immunization of melanoma patients with purified ganglioside In: HF Oettgen (ed) Ganglioside and Cancer. VCH, Weingein, Germany, pp 294
20. Livingston PO, Wong YC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves JM, Helling F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044
21. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immun 45:1-9
22. Meuillet E, Cremel G, Dreyfus H, Hicks D (1996) Defferential modulation of basic fibroblast and epidermal growth factor receptor activation by ganglioside GM3 in cultured retinal Müller glia. Glia 3:206-216
23. Meuillet EJ, Mania-Farnell B, George D, Inokuchi JI, Bremer EG (2000) Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431. Exp Cell Res 256:74-82
24. Molotkovskaya IM, Kholodenko RV, Zelenova NA, Sapozhnikov AM, Mikhalev II, Molotkovsky JG (2000) Gangliosides induce cell apoptosis in the cytotoxic line CTLL-2, but not in the promyelocyte leukemia cell line HL-60. Membr Cell Biol 13:811-822
25. Nakakuma H, Horikawa T, Kawaguchi T, Hidaka M, Nagakura S, Hirai S, Kageshita T, Ono T, Kagimoto T, Iwamori M (1992) Common phenotypic expression of ganglioside GM3 and GD3 in normal human tissue and neoplastic lesions. Jpn J Clin Oncol 22:308-312
26. Nores GA, Dohi T, Taniguchi M, Hakomori S (1987) Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen. J Immunol 139:3171-3176
27. Parajuli P, Yanagawa H, Hanibuchi M, Takeuchi E, Miki T, Yano S, Sone S (2001) Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients. Cancer Lett 165:179-184
28. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659-666
29. Ravindranath MH, Brazeau SM, Morton DL (1994a) Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 50:648-653
30. Ravindranath MH, Ravindranath RM, Morton DL, Graves MC (1994b) Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J Immunol Methods 169:257-272
31. Ritter G, Ritter-Boosfeld E, Adluri R, Calves M, Ren S, Yu KR, Oettgen HF, Old LJ, Livingston PO (1995) Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 62:668-672
32. Taniguchi M, Sakatsume M, Harada Y, Nores GA, Hakomori (1988) Analysis of melanoma antigen and its involvement in tumor-escape mechanism. Princess Takamatsu Symp 19:247-254
33. Van Lith ML, Kohlgraf KG, Sivinski CL, Tempero RM, Hollingsworth MA (2002) MUC1-specific antitumor responses: Molecular requirements for CD4-mediated responses. Int Immunol 14:873-882
34. Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R (2000) Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliósidos. Oncol Rep 7:751-756
35. Yamamura S, Handa K, Hakomori S (1997) A close association of GM3 with c-Scr and Rho in GM3-enriched microdomains at the B16 melanoma cell surface membrane: A preliminary note. Biochem Biophys Res Commun 236:218-222
36. Zhang H, Zhang S, Cheung NV, Ragupathi G, Livingston PO (1998) Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 58:2844-2849
37. Zhao XJ, Cheung NK (1995) GD2 oligosaccharide: Target for cytotoxic T lymphocytes. J Exp Med 182:67-74
38. Zheng M, Fang H, Tsuruoka T, Tsuji T, Sasaki T, Hakomori S (1993) Regulatory role of GM3 ganglioside in α5β1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells. J Biol Chem 268:2217-2222
39. Zhou Q, Hakomori S, Kitamura K, Igarashi Y (1994) GM3 directly inhibits tyrosine phosphorylation and de-N-acetyl-GM3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interacton. J Biol Chem 269:1959-1965